COLLCollegium Pharmaceutical, Inc.

$22.06-38% 1Y

$22.06

$21.8552 weeks$49.84

COLL in its own filings

Nothing in COLL's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

201

Events found in the filings · across 865 filings · the record starts in 2015

Hard flags: none
Hard flags
Most recent filing: Aug 13, 2026
Most recent filing · Form 8-K
Record starts: Mar 31, 2015
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 5, 2026
Change in certifying accountanthistorical: 2016-04-15
SEC comment-letter activity15 occurrences: 2020-03-27

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 13, 2026On August 12, 2026, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $50 million of the Company’s common stock.Other event · Form 8-K
May 12, 2026As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “Company”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“Commave Seller”), and Corium, LLC, a Delaware limited liability company …Acquisition or disposition completed · Form 8-K
May 7, 2026Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress.Earnings release · press release
Apr 7, 2026Departure of Directors or Principal Officers; Election of Directors Director Nominee On April 6, 2026, the board of directors (“Board”) of Collegium Pharmaceutical, Inc. (the “Company”) approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders (the “Annual …Director or officer change · Form 8-K
Mar 19, 2026Equity Purchase Agreement On March 19, 2026, Collegium Pharmaceutical, Inc. (the “Company”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“Commave Seller”), and Corium, LLC, a Delaware limited liability company …Material agreement entered · Form 8-K
Dec 30, 2025Entry into a Material Agreement. On December 23, 2025, Collegium Pharmaceutical, Inc. (the “Company”) entered into a Credit Agreement by and among the Company, the lenders from time to time party thereto and Truist Bank, as administrative agent (the “Credit Agreement”)Material agreement entered · Form 8-K
Nov 6, 2025Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance.Earnings release · press release